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A B S T R A C T
Purpose
The purpose of this study was to confirm overall survival (OS) and other clinical benefits with
bortezomib, melphalan, and prednisone (VMP) versus melphalan and prednisone (MP) in the phase
III VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial after prolonged follow-up,
and evaluate the impact of subsequent therapies.
Patients and Methods
Previously untreated symptomatic patients with myeloma ineligible for high-dose therapy received
up to nine 6-week cycles of VMP (n  344) or MP (n  338).
Results
With a median follow-up of 36.7 months, there was a 35% reduced risk of death with VMP versus
MP (hazard ratio, 0.653; P  .001); median OS was not reached with VMP versus 43 months with
MP; 3-year OS rates were 68.5% versus 54.0%. Response rates to subsequent thalidomide-
(41% v 53%) and lenalidomide-based therapies (59% v 52%) appeared similar after VMP or MP;
response rates to subsequent bortezomib-based therapy were 47% versus 59%. Among patients
treated with VMP (n  178) and MP (n  233), median survival from start of subsequent therapy
was 30.2 and 21.9 months, respectively, and there was no difference in survival from salvage
among patients who received subsequent bortezomib, thalidomide, or lenalidomide. Rates of
adverse events were higher with VMP versus MP during cycles 1 to 4, but similar during cycles
5 to 9. With VMP, 79% of peripheral neuropathy events improved within a median of 1.9 months;
60% completely resolved within a median of 5.7 months.
Conclusion
VMP significantly prolongs OS versus MP after lengthy follow-up and extensive subsequent antimy-
eloma therapy. First-line bortezomib use does not induce more resistant relapse. VMP used upfront
appears more beneficial than first treating with conventional agents and saving bortezomib- and
other novel agent–based treatment until relapse.
J Clin Oncol 28:2259-2266. © 2010 by American Society of Clinical Oncology
INTRODUCTION
In the absence of curative therapy, the goal of
treatment for multiple myeloma (MM) is pro-
longed overall survival (OS). Recent studies have
suggested that over the past decade, the introduc-
tion of high-dose therapy for eligible patients
age  65 years and the novel agents bortezomib,
thalidomide, and lenalidomide as rescue thera-
pies has increased OS for patients with MM.1-3
However, improvements have been less prono-
unced in elderly patients1-3; the unmet need in this
population may be addressed through optimal use
of chemotherapy plus novel agents.1,4-7
Use of novel agent–based regimens in previ-
ously untreated patients ineligible for high-dose
therapy has resulted in improved response rates
and long-term outcomes, such as time to progres-
sion (TTP) and progression-free survival (PFS),
compared with conventional regimens.8 However,
analysis of OS is becoming increasingly complicated
due to the impact of novel agents as rescue therapies.
Indeed, only two4,9 of five4,6,9-11 phase III trials of
thalidomide plus melphalan and prednisone (MPT)
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versus melphalan and prednisone (MP) have shown an OS benefit
with MPT. Moreover, it has been suggested that first-line use of
novelagents,althoughinitiallymoreeffectivethanconventionalchem-
otherapy regimens, could induce more resistant relapses.7,12-14 Ac-
cordingly, it is of increasing interest to analyze response to subsequent
therapies in patients treated upfront with novel agents.
The first report of the international, randomized phase III VISTA
trial demonstrated superior efficacy with bortezomib plus melphalan
and prednisone (VMP) versus MP in previously untreated patients
with MM ineligible for high-dose therapy.15 Follow-up was limited at
first analysis (median, 16.3 months); 12% of patients remained on
therapy.15 We now present updated analyses of OS, time to next
therapy (TNT), and treatment-free interval (TFI) to determine
whether initial findings of superior efficacy with VMP versus MP are
confirmed after prolonged follow-up and more extensive use of sub-
sequent therapy. We also focus on survival from the start of subse-
quent therapy and response to rescue therapies, to explore whether
VMP induced more resistant relapses than MP, and whether VMP
used upfront appeared more beneficial than using conventional treat-
ment upfront and saving novel agents until relapse.
PATIENTS AND METHODS
Patients and Study Design
VISTA study details have been reported.15 Briefly, patients with pre-
viously untreated MM who were ineligible for high-dose therapy were
randomly assigned to receive nine 6-week cycles of VMP, comprising
bortezomib 1.3 mg/m2 (days 1, 4, 8, 11, 22, 25, 29, 32, cycles 1 to 4; days 1,
8, 22, 29, cycles 5 to 9) plus melphalan 9 mg/m2 and prednisone 60 mg/m2
(days 1 to 4, all cycles), or MP. Patients with serum creatinine higher than
2 mg/dL or grade  2 peripheral neuropathy or neuropathic pain by
National Cancer Institute Common Toxicity Criteria for Adverse Events
version 3.0 were excluded.
Response and progression were assessed every 3 weeks during treat-
ment and then every 8 weeks until disease progression according to Euro-
pean Group for Blood and Marrow Transplantation criteria,16 using a
central laboratory for M-protein quantification and immunofixation and a
validated algorithm. Patients were then followed at least every 12 weeks for
survival and subsequent therapy use. Safety was assessed until 30 days
postlast dose of study drug; adverse events (AEs) were graded according to
National Cancer Institute Common Toxicity Criteria for Adverse Events
version 3.0. All patients provided written informed consent. Review boards
at all participating institutions approved the study, which was conducted
according to the provisions of the Declaration of Helsinki, the Interna-
tional Conference on Harmonization, and the Guidelines for Good Clini-
cal Practice.
Initial and Updated Analyses
VISTA was stopped at the third preplanned interim analysis based on
independent data monitoring committee recommendation, as the statistical
boundary for the primary end point, TTP, had been crossed. Data cutoff was
June 15, 2007; median follow-up was 16.3 months.15 Eighty patients remained
on treatment (47 VMP, 33 MP).15
Updated analyses were performed using data collected through March
16, 2009. After the study was stopped, formal centralized collection of
M-protein data was stopped and thus subsequent data on response rates, TTP,
Assessed for eligibility
(N = 755)
Excluded
(n = 73)
Randomly assigned
(n = 682)
Allocated to melphalan–prednisone (n = 338)
Received treatment (n = 337)
Did not receive treatment (n = 1)
  Adverse event (renal insufficiency)
Allocated to bortezomib plus
  melphalan–prednisone (n = 344)
Received treatment (n = 340)
Did not receive treatment (n = 4)
  Patient choice (n = 3)
  Other  (n = 1)
Treatment completed (n = 169)
Discontinued treatment (n = 168)
  Progressive disease (n = 73)
  Adverse event (n = 48)
  Patient choice (n = 19)
  Death (n = 17)
  Maintenance of complete response (n = 1)
  Other (n = 10)
Treatment completed (n = 199)
Discontinued treatment (n = 141)
  Progressive disease (n = 24)
  Adverse event (n = 52)
  Patient choice (n = 32)
  Death (n = 14)
  Maintenance of complete response (n = 9)
  Other (n = 10)
Analyzed for response (n = 331)
Excluded from response analysis (n = 6)
No measurable disease at baseline (n = 6)
Analyzed for response (n = 337)
Excluded from response analysis (n = 3)
No measurable disease at baseline (n = 3)
Received subsequent therapy (n = 233)
Did not receive subsequent therapy (n = 105)
  Not yet required (n = 92)
  Died due to PD prior to receiving 
    subsequent therapy (n = 13)
Received subsequent therapy (n = 178)
Did not receive subsequent therapy (n = 166)
  Not yet required (n = 159)
  Died due to PD prior to receiving
    subsequent therapy (n = 7)
Fig 1. CONSORT diagram. PD, progres-
sive disease.
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and PFS were not updated because the information would not have been based
on the same stringent methodology as the initial analysis. Data collection
continued for OS, subsequent therapy use, best responses to subsequent ther-
apies as reported by investigators, and safety, including improvement/resolu-
tion of AEs (until 30 days post-treatment completion).
Statistical Analysis
OS (random assignment until death), TNT (random assignment until
first dose of subsequent anti-MM therapy), and TFI (last dose of VISTA study
drug until first dose of subsequent anti-MM therapy) were analyzed using
Kaplan-Meier methodology. Time-to-event data were compared between
arms using stratified log-rank tests in intent-to-treat analyses. In posthoc
analyses among patients treated with VMP, OS was evaluated within sub-
groups with/without poor prognostic characteristics, including advanced
age, impaired renal function, and high-risk cytogenetics. In exploratory
posthoc analyses, survival was evaluated from random assignment and
from start of subsequent therapy by arm in patients who had received any
subsequent therapy and according to subsequent therapy received. Safety
was analyzed in all patients who received at least one dose of study drug.
Rates of treatment-emergent AEs were analyzed overall and by treat-
ment cycle.
RESULTS
Patient Characteristics and Disposition
A total of 682 patients were randomly assigned to receive VMP
(n  344) or MP (n  338). Baseline demographics and disease
characteristics were previously reported,15 and are summarized in
Appendix Table A1 (online only). Overall, median age was 71 years,
30% of patients were age 75 years, 34% had International Staging
System17 stage III MM, and 33% had 2-microglobulin higher than
5.5 mg/L. At the initial analysis, VMP was superior to MP across all
efficacy end points, including response rate (71% v 35%), complete
response (CR) rate (30% v 4%), TTP (median, 24.0 v 16.6 months;
hazard ratio [HR], 0.48; P  .001), and OS (HR, 0.61; P  .008).15
Data not updated (see Patients and Methods) are summarized in
Appendix Table A2 (online only).
Updated patient disposition at data cutoff for this analysis
(March 16, 2009) is shown in Figure 1 (CONSORT). All patients have
completed VISTA study treatment. Median number of treatment
No. of patients at risk
MP 338 320 301 284 262 249 240 230 216 203 185 143 103 68 41 15 3
VMP 344 315 300 295 288 280 270 260 246 241 221 173 124 84 54 23 1
Median follow-up: 36.7 months
VMP: Median OS not reached (109 deaths)
MP: Median OS, 43.1 months (148 deaths)
HR = 0.653 (95% CI, 0.508 to 0.840); P = .0008
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MP 233 233 226 214 202 192 184 176 165 155 143 113 82 58 36 12 1
VMP 178 177 175 174 169 164 156 148 137 134 122 101 79 58 36 15 2
VMP: Median OS not reached (61 deaths)
MP: Median OS, 45.0 months (104 deaths)
HR = 0.688 (95% CI, 0.500 to 0.948); P = .021
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MP 233 195 170 137 119 94 67 53 46 27 24 14 9 4 2 0
VMP 178 151 126 106 86 62 49 36 28 21 16 12 8 4 1 1
VMP: Median survival, 30.2 months (61 deaths)
MP: Median survival, 21.9 months (104 deaths)
HR = 0.815 (95% CI, 0.590 to 1.125); P = .21
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No. of patients at risk
MP 186 164 149 124 109 86 61 47 40 24 21 11 7 4 2 0
VMP 135 119 101 84 67 48 39 26 19 13 10 8 6 3 1 1
VMP: Median survival, 27.8 months (44 deaths)
MP: Median survival, 26.3 months (77 deaths)
HR = 0.891 (95% CI, 0.609 to 1.301); P = .55
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Fig 2. Overall survival (OS) from random assignment in the bortezomib, melphalan, and prednisone (VMP) and melphalan and prednisone (MP) arms in (A) the overall
population (ITT analysis), and (B) only patients randomly assigned to VMP or MP who had received subsequent therapy by data cutoff for the present analysis. Survival
from the start of second-line therapy in (C) all patients who had received subsequent therapy, and (D) patients who received any subsequent novel agents. HR,
hazard ratio.
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cycles administered was nine (50 weeks) and eight (48 weeks) in the
VMP and MP arms, respectively.
OS
After median follow-up of 36.7 months, OS was prolonged with
VMP versus MP (HR, 0.653; P .001), with VMP associated with a
35% reduced risk of death. Median OS was not estimable versus 43.1
months in the VMP and MP arms, respectively, with 109 (32%) and
148 (44%) patients having died (Fig 2A); 3-year OS rates were 68.5%
versus 54.0%, respectively. The improved OS with VMP versus MP in
patient subgroups predefined by age, sex, race, 2-microglobulin,
albumin, region, International Staging System stage, and creatinine
clearance is shown in Appendix Figure A1 (online only).
Subsequent Therapy
At data cutoff, 178 (52%) and 233 patients (69%) in the VMP and
MP arms, respectively, had received subsequent therapy. TNT and TFI
with VMP versus MP are shown in Figure 3; median TNT was 28.1
months versus 19.2 months (HR, 0.527; P .001), and median TFI
was 17.6 months versus 8.4 months (HR, 0.543; P .001). In the VMP
and MP arms, 42.7% and 18.1% of patients, respectively, had a TFI
of 2 years.
Novel agents received as part of subsequent anti-MM therapy are
summarized in Appendix Table A3 (online only). Among patients
who received subsequent therapy in the VMP and MP arms, respec-
tively, 43 (24%) and 116 (50%) received bortezomib, 81 (46%) and
110 (47%) received thalidomide, and 57 (32%) and 30 (13%) received
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No. of patients at risk
MP 338 307 259 229 204 177 149 126 101 77 59 40 27 12 6 3 1
VMP 344 310 283 267 252 235 211 189 165 143 126 88 56 30 21 9 0
VMP: Median TNT, 28.1 months (185 events)
MP: Median TNT, 19.2 months (246 events)
HR = 0.527 (95% CI, 0.433 to 0.642); P < .001
No. of patients at risk
MP 337 208 163 138 111 82 65 47 36 18 11 5 2 1 1
VMP 340 256 225 202 170 152 131 96 70 37 24 13 3 0 0
VMP: Median TFI, 17.6 months (185 events)
MP: Median TFI, 8.4 months (246 events)
HR = 0.543 (95% CI, 0.446 to 0.661); P < .001
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Fig 3. (A) Time to next therapy (TNT) and (B) treatment-free interval (TFI) with bortezomib, melphalan, and prednisone (VMP) and melphalan and prednisone (MP). HR,
hazard ratio.
Table 1. Investigator-Reported Best Responses (including for current subsequent therapy if ongoing for  3 months at data cutoff) to Second-Line,
Third-Line, and Beyond, and Any Subsequent (second-line and beyond) Bortezomib-, Thalidomide-, and Lenalidomide-Based Therapy in Patients Originally
Randomly Assigned to the VMP and MP Arms
Subsequent Therapy and
Responses Achieved
Arm by Line
VMP MP
2nd  3rd Any 2nd  3rd Any
No. % No. % No. % No. % No. % No. %
Bortezomib-based therapy (No. with data/No. total) 22/25 17/21 36/43 76/82 49/50 109/116
CR  PR† 9 41 8 47 17 47 45 59 27 55 64 59
CR† 2 9 0 2 6 6 8 5 10 9 8
Thalidomide-based therapy (No. with data/No. total) 63/71 19/23 73/81 73/84 38/44 97/110
CR  PR† 23 37 10 53 30 41 34 47 21 55 51 53
CR† 2 3 0 2 3 1 1 4 11 5 5
Lenalidomide-based therapy (No. with data/No. total) 22/26 27/34 46/57 9/10 14/21 23/30
CR  PR† 16 73 12 44 27 59 6 67 6 43 12 52
CR† 2 9 2 7 4 9 1 11 0 1 4
Abbreviations: VMP, bortezomib, melphalan, and prednisone; MP, melphalan and prednisone; CR, complete response; PR, partial response.
Patients could have received more than one agent, either within the same combination regimen, as part of consecutive separate regimens within the same line
of therapy, or as part of separate regimens within different subsequent lines of therapy. These patients are included in each of the relevant groups.
†Percentage response rates calculated using the number of patients with data as the denominator. No. with data represents the numbers of patients for whom
the investigators reported the response to subsequent therapy; in each arm, responses to subsequent therapy were unknown or missing for some of the total
number of patients who received the subsequent therapy.
Mateos et al
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lenalidomide. Investigator-reported best responses to novel agent–
based subsequent therapies are summarized in Table 1. Response rates
to second-line bortezomib-, thalidomide-, and lenalidomide-based
therapies were 41%, 37%, and 73%, respectively, after VMP, and 59%,
47%, and 67%, respectively, after MP; respective response rates to
therapies received at third line and beyond were 47%, 53%, and 44%
after VMP, and 55%, 55%, and 43% after MP. Efficacy of bortezomib-
based re-treatment as second-line therapy in patients randomly as-
signed to VMP was evaluated according to TFI. Among 16 patients
with TFI  12 months, response rate was 25%, including 6% CR.
Among nine patients with TFI longer than 12 months, response rate
(in seven with response reported) was 71%, including 14% CR.
Figure 2B shows OS from initial random assignment among
patients treated with VMP and MP who received subsequent therapy
(HR, 0.688; P .021); 3-year OS rates were 67.9% and 55.9%, respec-
tively. The OS advantage with VMP was also seen versus the subgroup
of patients treated with MP who received bortezomib as second-line
therapy (data not shown). Median survival from start of subsequent
therapy was 30.2 and 21.9 months after VMP and MP, respectively
(Fig 2C; HR, 0.815; P  .21). Notably, survival from start of subse-
quent therapy was similar after VMP versus MP among patients who
received any novel agents as subsequent therapy (Fig 2D; median
27.8 v 26.3 months; HR, 0.891; P  .55) and among patients who
received subsequent thalidomide and lenalidomide but no bort-
ezomib (median 27.8 months v not reached; HR, 0.766; P .35).
VMP Subgroup Analyses
Within the VMP arm, OS was longer among patients age
younger than 75 versus 75 years (HR, 1.664; P .011; 3-year OS:
74.1% v 55.5%; Fig 4A). By contrast, there were no statistically signif-
icant differences although there were trends to longer OS among
patients with creatinine clearance 60 versus fewer than 60 mL/min
(HR, 1.291; P .238; 3-year OS: 74.5% v 63.1%; Fig 4B), and patients
with standard risk versus high-risk cytogenetics (HR, 1.346; P .399;
3-year OS 71.6% v 56.1%; Fig 4C).
Novel agents received as part of subsequent therapy according
to age, baseline creatinine clearance, and cytogenetics are summa-
rized in Appendix Table A4 (online only). Survival from start of
subsequent therapy appeared shorter among patients with creatinine
Fig 4. Overall survival (OS) from random assignment in the bortezomib, melphalan, and prednisone arm in patients (A) age  75 and older than 75 years, (B) with
creatinine clearance (CrCl)  60 and shorter than 60 mL/min, (C) with standard-risk (std) and high-risk (t(4;14), t(14;16), del(17p)) cytogenetics (cyto) by fluorescence
in situ hybridization. HR, hazard ratio.
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clearance shorter than 60 versus  60 mL/min who received subse-
quent thalidomide and lenalidomide but no bortezomib (Appendix
Fig A2A, online only); no difference was apparent among the small
number of patients who received subsequent bortezomib but no tha-
lidomide and lenalidomide (Appendix Fig A2B). TNT was similar
between patients with high-risk versus standard-risk cytogenetics
(median 24.1 v 27.4 months; HR, 1.478; P .17); survival from start of
subsequent therapy appeared similar between cytogenetic risk groups
among patients who received any subsequent novel agent–based ther-
apy (Appendix Fig A2C) but substantially shorter in two high-risk (6
and 15.5 months) versus 17 standard-risk patients (median, 30.8
months) who received no subsequent novel agents.
Safety
Safety profiles were similar to those reported at the initial analy-
sis.15 Rates of on-study deaths were similar between the VMP (n19;
6%) and MP (n  14; 4%) arms, including 2% treatment-related
deaths on each arm. Rates of treatment discontinuation due to AEs
remained similar (15%/14% in the VMP/MP arms). Grade 3/4 AEs that
occurred at an incidence of 5% in either arm are presented in Table 2.
The rate of peripheral neuropathy with VMP was almost identi-
cal to that reported at the initial analysis.15 After prolonged follow-up,
79% of peripheral neuropathy events had improved/resolved within a
median of 1.9 months, while 60% completely resolved within a me-
dian of 5.7 months. Among 159 patients who had peripheral neurop-
athy while receiving VMP, 21 (13%), 36 (23%), and 39 (25%) have
received subsequent bortezomib-, thalidomide-, and lenalidomide-
based therapy, respectively, compared with 22 (12%), 45 (24%), and
18 (10%), respectively, of the 185 patients who did not report peripheral
neuropathy. Among 21 patients who had peripheral neuropathy during
VMP therapy and subsequently received bortezomib-based therapy, 16
(76%)hadat leastoneevent improved/resolved, including12(57%)with
at least one event resolved, by the start of subsequent therapy.
VMP and MP safety profiles by treatment cycle are summarized
in Table 3. Rates of AEs were higher with VMP versus MP during
cycles 1 to 4, but similar during cycles 5 to 9. Rates of AEs, grade 3
AEs, serious AEs, and discontinuations due to AEs in the VMP arm
were lower during cycles 5 to 9 compared with cycles 1 to 4. In the MP
arm, rates of grade  3 AEs and discontinuations due to AEs were
similar in cycles 1 to 4 and cycles 5 to 9.
DISCUSSION
The results of this updated analysis of the international phase III
VISTA trial after prolonged follow-up (median, 36.7 months) con-
firm that VMP results in significantly longer OS compared with MP in
previously untreated patients with MM who are ineligible for high-
dose therapy. This OS benefit was seen consistently across patient
subgroups predefined by baseline characteristics, including age, dis-
ease stage, and creatinine clearance.
This confirmed survival advantage represents an important find-
ing, as an OS benefit has not been consistently reported in other
studies of novel agent–based regimens versus MP. For example, an OS
benefit was reported in two studies of MPT versus MP by the Inter-
groupe Francophone du Mye´lome,4,9 but not in three other similar
phase III studies.6,10,11 One reason suggested for the lack of OS benefit
with MPT was the confounding impact of subsequent therapies con-
taining novel agents in patients receiving MP upfront.6,11
However, in VISTA, the OS benefit with VMP versus MP was
seen both overall and in an analysis restricted to patients who had
received subsequent therapy, despite 50% of patients treated with MP
being rescued with bortezomib-based therapy in the relapsed setting.
Indeed, this benefit was retained with VMP versus MP followed by
bortezomib as second-line therapy. Thus, our results indicate that
using bortezomib-based treatment in the first-line setting provides
greater survival benefit to patients compared with the approach of
administering first-line treatment with conventional agents and sav-
ing bortezomib- and other novel agent–based treatment for salvage.
Patients receiving VMP experienced greater clinical benefit ver-
sus those receiving MP in terms of TNT and TFI. Among patients who
had received subsequent therapy, taking into consideration potential
differences in the order in which subsequent therapies were received,
as well as the possible confounding factor of the different proportions
Table 2. Grade 3 and 4 Adverse Events Occurring in  5% of Patients in
Either the VMP or MP Arm
Adverse Event
Arm by Grade (%)
VMP
(n  340)
MP
(n  337)
3 4 3 4
Neutropenia 29 11 23 15
Thrombocytopenia 20 18 16 15
Anemia 16 3 20 8
Leukopenia 21 3 16 4
Lymphopenia 14 6 9 2
Peripheral sensory neuropathy 13  1 0 0
Neuralgia 8 1  1 0
Fatigue 7 1 2 0
Diarrhea 7 1 1 0
Pneumonia 5 2 4 1
Hypokalemia 6 1 2 1
Asthenia 6  1 3 0
Abbreviations: VMP, bortezomib, melphalan, and prednisone; MP, melphalan
and prednisone.
Table 3. Tolerability of VMP and MP Therapy by Treatment Cycle
Parameter
Cycle (%)
VMP MP
All 1-4 5-9 All 1-4 5-9
No. of patients 340 340 249 337 337 234
Any treatment-emergent adverse
event 99 99 91 97 95 88
Grade 1 maximum severity 1 NA NA 3 NA NA
Grade 2 maximum severity 8 NA NA 14 NA NA
Any grade  3 treatment-emergent
adverse event 91 85 62 80 66 63
Grade 3 maximum severity 53 NA NA 44 NA NA
Grade 4 maximum severity 29 NA NA 28 NA NA
Any serious adverse event 46 40 14 36 29 16
Discontinuation of regimen
because of adverse events 15 12 5 14 8 7
Abbreviations: VMP, bortezomib, melphalan, and prednisone; MP, melphalan
and prednisone; NA, not assessable.
Data represent discontinuation of all treatment; in addition, 19% of VMP
patients discontinued bortezomib but remained on MP, 15% and 4% during
cycles 1-4 and 5-9, respectively.
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of patients on each arm who had received subsequent therapy, re-
sponse rates to subsequent thalidomide- and lenalidomide-based
therapies appeared similar between arms. Furthermore, re-treatment
with bortezomib-based therapies after VMP was effective; the 47%
response rate reflects similar findings in studies of bortezomib-based
re-treatment in relapsed MM.18-22 As might be expected, the response
rate to subsequent bortezomib-based therapies appeared somewhat
higher in bortezomib-naïve patients after MP (59%). Survival from
start of subsequent therapy was not shorter, and may even be longer,
among patients randomly assigned to VMP versus MP (median 30.2 v
21.9 months). Importantly, there was no difference between arms in
survival from start of subsequent therapy among patients who re-
ceived any subsequent novel agents. Our findings indicate that pa-
tients relapsing after bortezomib-based therapy are not intrinsically
more resistant to subsequent therapies, and can be as successfully
treated with subsequent immunomodulator-based therapies, com-
pared with those relapsing after traditional chemotherapy with MP;
VMP treatment does not appear to select a more resistant clone.
Within the VMP arm, OS was longer among patients younger
than 75 versus 75 years, reflecting the expected adverse impact on
survival of advanced age. Nonstatistically significant differences in OS
were seen among patients treated with VMP with or without renal
impairment and high-risk cytogenetics. Notably, OS curves appeared
similar until approximately 24 to 28 months (median TTP/TNT), and
subsequently appeared to show greater divergence with a trend to
shorter OS for patients with adverse characteristics. Regarding this
apparent impact of renal impairment, our findings indicated that
among patients treated with VMP who received subsequent therapy
including thalidomide and lenalidomide but not bortezomib, survival
from start of subsequent therapy was longer in patients with creatinine
clearance60 versus lower than 60 mL/min. By contrast, survival did
not appear affected by renal function among patients who received
subsequent bortezomib but not thalidomide and lenalidomide. How-
ever, these are retrospective analyses, and should thus be interpreted
with caution. Regarding outcomes among patients treated with VMP
with high-risk cytogenetics, we observed similar survival from start of
subsequent therapy among 15 high-risk and 57 standard-risk patients
who received novel agent–based rescue therapies. Thus, a possible
interpretation of the trend toward shorter OS among patients with
high-riskversusstandard-riskcytogeneticsisthattherewasatrendtoward
earlier receipt of subsequent therapy in high-risk patients, and that two of
17 high-risk patients were not exposed to novel agents after relapse and
had notably poor survival from start of subsequent therapy. However, the
small number of patients treated with VMP with high-risk cytogenetics
precludes drawing any firm conclusions. At the initial analysis, response
rates and TTP with VMP were similar among patients with or without
these adverse characteristics.15 Overall, our findings reflect those from a
pilot phase I to II study of VMP23 and preliminary data from other phase
III studies of modified VMP regimens,24,25 in which high-risk cytogenet-
ics did not affect response rates,23-25 TTP,23 or PFS.25 Similarly, high-risk
cytogenetics did not affect response rates with other bortezomib-based
regimens in previously untreated patients with MM.26-29
At this updated analysis, after completion of therapy among 80
patients who were ongoing at the initial analysis, the overall safety
profiles of VMP and MP were essentially unchanged. VMP was gen-
erally well-tolerated, with manageable toxicities. Our analysis of
treatment-emergent AEs by treatment cycle demonstrated that toxic-
ities associated with VMP were substantially lower during cycles 5 to 9
versus cycles 1 to 4 and similar to those associated with MP. Thus,
while initial substantial tumor-burden reduction with twice-weekly
bortezomib during cycles 1 to 4 was associated with somewhat more
frequent toxicities with VMP versus MP, tolerability was improved
and comparable to MP during weekly bortezomib maintenance (cy-
cles 5 to 9), with improved responses and an increased CR rate from the
end of cycle 4.30 Regimens using weekly bortezomib dosing schedules are
currently under investigation24,25 and showing a clear reduction in toxic-
ity, but longer follow-up is needed to confirm if efficacy is maintained.
After prolonged follow-up, the rate of improvement or resolu-
tion of peripheral neuropathy events on the VMP arm was 79%,
demonstrating that this toxicity is reversible in the majority of cases.
Indeed, 60% of events had resolved completely to baseline by data
cutoff, within a median of 5.7 months. Our findings are supported by
data on reversibility of peripheral neuropathy with single-agent bort-
ezomib in first-line31 and relapsed32 MM.
In conclusion, this updated analysis of VISTA supports the strat-
egy of using bortezomib-based treatment as first-line therapy instead
of as salvage after upfront conventional therapy. Our results confirm
the significant survival benefit and the other clinical benefits of TNT
and TFI with VMP versus MP. The survival benefit was demonstrated
even with the use of subsequent novel agent–based therapies in pa-
tients treated with MP alone upfront. Indeed, salvage therapies ap-
peared similarly effective in patients initially randomly assigned to
VMP or MP, demonstrating that the use of bortezomib upfront does
not preclude the successful use of novel agents at relapse. Moreover,
postrelapse survival even appeared longer after VMP, indicating that
first-line bortezomib use does not induce more resistant relapse.
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